IGF-1 LR3 Peptide Dosing Guide: Cycle, Side Effects & Safety (2026)

IGF-1 LR3 is a synthetic, longer-acting analog of insulin-like growth factor 1 (IGF-1). The body's own IGF-1 carries growth signals from the liver to muscle, bone, and other tissues. IGF-1 LR3 is engineered to do the same thing, but for a much longer period of time and without being captured by the proteins that normally limit IGF-1 activity.

Two structural changes drive the difference. The peptide has an arginine in place of glutamic acid at position 3, and an extra 13-amino-acid extension on the front (the N-terminus), making the full chain 83 amino acids instead of native IGF-1's 70. These modifications cut its affinity for IGF binding proteins and stretch the half-life to roughly 20-30 hours.

There is no oral or topical version of IGF-1 LR3 in research use. The only practical research format is a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water and injected subcutaneously or intramuscularly. This page treats injection as the only route.

IGF-1 LR3 dosing is reported in micrograms (mcg), not milligrams. Doses are small, so syringe accuracy matters. Community protocols generally cluster between 20 and 100 mcg per day, given as one daily injection because of the long half-life. None of these ranges come from a published human clinical trial of IGF-1 LR3 — they are extrapolated from preclinical work, the Increlex (mecasermin) clinical record, and decades of community reporting.

Timing rules across both routes. Eat 30-50 grams of fast-acting carbohydrates within roughly 30 minutes of every injection. Never inject in a fasted state. Never inject within 2 hours of bedtime — overnight hypoglycemia is the highest-risk scenario. Skip a missed dose and resume on schedule the next day. Never double-dose to compensate.

IGF-1 LR3 ships as a freeze-dried powder. Before use it has to be dissolved in bacteriostatic water (BAC water) — water with 0.9% benzyl alcohol that prevents microbial growth. Plain saline or sterile water are not appropriate substitutes for multi-dose vials.

IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor present on most tissues — skeletal muscle, bone, liver, kidney, nerve, and connective tissue. When the receptor is engaged, it kicks off intracellular signaling cascades that drive both protein-building activity and cell proliferation.

PI3K → Akt → mTOR. This is the protein-synthesis arm. It increases muscle protein synthesis, reduces protein breakdown, supports glucose and amino acid uptake, and suppresses programmed cell death. It is also the pathway that drives IGF-1 LR3's insulin-like glucose-lowering effect — the same mechanism that creates hypoglycemia risk.

RAS → RAF → MEK → ERK (MAPK). This is the proliferation arm. It supports cell division and tissue growth. In skeletal muscle this pathway can support satellite cell activation and possible hyperplasia (creation of new muscle fibers). The same mitogenic activity is the basis of long-term cancer concern, because IGF-1 signaling is one of the more well-documented growth pathways studied in tumor biology.

Native IGF-1 is largely sequestered in circulation by IGF binding proteins (IGFBPs) — a family of six proteins that escort IGF-1 around the body and limit how much is free to engage receptors. The structural changes in IGF-1 LR3 (the arginine substitution and 13-amino-acid extension) drop binding-protein affinity sharply. More peptide stays free, and the half-life stretches from roughly 12-15 hours for native IGF-1 to about 20-30 hours for IGF-1 LR3. Tomas et al. (1996) reported the analog was 1.5-2x more potent than equimolar IGF-1 in catabolic rat models, and broader pharmacology literature places it at roughly 3x potency overall.

These same pharmacology properties — direct receptor activation, reduced binding-protein clearance, and the long half-life — explain both the anabolic interest researchers have in IGF-1 LR3 and its primary safety liabilities.

IGF-1 LR3 has no FDA-approved human indication. It is studied as a research compound and used in research-community protocols only. The Increlex (mecasermin) FDA label, which covers native rhIGF-1 in pediatric severe primary IGFD, is the closest human reference and informs the contraindications below.

Active or prior cancer, or strong family history of cancer. IGF-1 signaling is mitogenic and anti-apoptotic. The Increlex label explicitly contraindicates use in patients with active or suspected neoplasia and notes that active or suspected malignancy should prompt discontinuation. Epidemiological studies have repeatedly linked elevated circulating IGF-1 to risk of certain cancers (LeRoith & Roberts 2003; Pollak 2008).

Diabetes (type 1 or type 2) or any condition involving glucose dysregulation. IGF-1 LR3 lowers blood glucose. Adding it to existing insulin therapy or impaired glucose handling can produce unpredictable, severe hypoglycemia. The 2025 Increlex label requires meal/snack pairing and dose titration starting from a low dose specifically because hypoglycemia is so consistent.

Pregnancy and breastfeeding. No human safety data exists. The Increlex label specifies it should not be used by pregnant women.

Closed or near-closed epiphyses being a goal of approved use. Mecasermin loses approved indication once growth plates close. For IGF-1 LR3, that means there is no validated 'normal-adult' indication at all. Adolescents with open growth plates are not appropriate research subjects in unsupervised settings due to disproportionate-growth concerns.

Concurrent insulin or insulin secretagogue therapy. Combining IGF-1 LR3 with insulin or sulfonylureas produces additive hypoglycemia. Multiple research-community sources flag this combination as having been associated with hospitalizations. There is no protocol justification for combining the two outside direct clinician supervision.

Pre-existing cardiac, kidney, liver, or splenic conditions. IGF-1 supports growth in many organ systems. Increlex labeling notes rapid increases in renal and splenic length in some treated patients. Pre-existing organ disease is widely treated as a hard contraindication.

Competitive athletes in tested sports. IGF-1 LR3 is prohibited at all times by the World Anti-Doping Agency (WADA) and by all major professional sports organizations. Detection assays for LR3 have been published in peer-reviewed analytical literature (Mongongu et al. 2020).

There are no published human clinical trials of IGF-1 LR3 itself. The closest safety dataset is the Increlex (mecasermin) clinical program, which followed 71 pediatric patients with severe primary IGFD on twice-daily SubQ rhIGF-1 for a mean of 3.9 years (some patients up to 11.5 years). The figures below are from the FDA-approved Increlex labeling.

In the Increlex program, hypoglycemia was reported in 30 of 71 subjects (42%). Most events were mild or moderate. Five subjects had severe hypoglycemia requiring assistance, and four experienced hypoglycemic seizures or loss of consciousness on at least one occasion. The rate was highest in the first month of treatment. Symptoms include shakiness, sweating, hunger, anxiety, confusion, dizziness, blurred vision, and at the severe end, seizure or loss of consciousness.

Mitigation in the Increlex label is straightforward: administer with food, never on an empty stomach, monitor glucose during titration, and keep fast-acting carbohydrates available. The IGF-1 LR3 research community uses the same rule set, with the additional precaution of avoiding pre-bed dosing because of overnight hypoglycemia risk.

Tonsillar hypertrophy was reported in roughly 15% of Increlex subjects. Adenoidal hypertrophy and snoring/sleep apnea were also documented. The mechanism is consistent with general lymphoid tissue growth under elevated IGF-1 exposure.

Intracranial hypertension occurred in 3 of the 71 Increlex subjects. The label recommends funduscopic examination at the start of therapy and periodically. New, severe, or persistent headache — especially with visual changes — warrants medical evaluation.

Increlex labeling notes rapid increases in renal and splenic length in some patients. In the research community, sustained or supraphysiologic IGF-1 exposure is associated with progressive abdominal distension (sometimes called 'GH gut') and concern for cardiac hypertrophy. Organ-growth changes are believed to be largely irreversible, which is the strongest argument behind the 4-6 week cycle ceiling.

Mild edema, joint stiffness, and headaches are commonly reported in the IGF-1 pathway literature, including IGF-1 LR3 community reports. These are typically dose-dependent and reversible with dose reduction or cycle discontinuation.

Lipohypertrophy, irritation, redness, and bruising can occur at injection sites. Site rotation and proper technique reduce frequency. The Increlex label also identifies injection-site lipohypertrophy as a recognized adverse reaction.

IGF-1 signaling is mitogenic and anti-apoptotic, two properties relevant to cancer biology. In 2-year rat carcinogenicity studies referenced in the Increlex label, increased mammary and skin tumor incidence occurred at high IGF-1 exposure. Tomas et al. (1997) reported that IGF-1 LR3 supported protein turnover in tumor-bearing rats but also increased tumor growth in that model. Broader epidemiology (LeRoith 2003; Pollak 2008) has linked higher circulating IGF-1 to elevated risk of certain cancers in human cohorts. This is not the same as proving short-term IGF-1 LR3 use causes cancer in healthy adults — it is a real biological-mechanism concern that supports cycle limits and absolute contraindication in anyone with cancer history.

Exogenous IGF-1 can suppress pituitary GH secretion through hypothalamic-pituitary feedback. This is one reason most IGF-1 LR3 protocols avoid late-evening dosing — dosing close to bedtime is more likely to coincide with the natural overnight GH pulse.

There is no validated efficacy timeline for IGF-1 LR3 in humans. The framework below combines what the Increlex (mecasermin) program tracked and what research-community protocols routinely report. It is a monitoring framework, not a results promise.

Stopping points reported in research community protocols. Persistent or severe hypoglycemic episodes despite proper meal timing. Progressive abdominal distension or waist increase that cannot be explained by training/nutrition. New persistent headaches, especially with visual symptoms (consistent with intracranial-hypertension warning in the Increlex label). Any new or growing lump, mole, or skin lesion — IGF-1 LR3 is not advisable in any context that could be malignant.

The pattern is consistent: strong mechanistic plausibility from preclinical data and adjacent human safety, no direct human efficacy or long-term safety data on IGF-1 LR3 itself. Any claim about expected human results in performance contexts goes beyond the published evidence.

Protect from light, avoid freeze-thaw cycles on reconstituted solution, and inspect the vial for clarity and absence of particles before each draw. Use a fresh sterile syringe for every administration. Discard reconstituted vials at the end of the listed window even if liquid remains.

If symptoms ever escalate beyond what oral glucose can manage, treat it as a medical emergency. Severe hypoglycemia caused 4 hospital-grade seizures or loss-of-consciousness events out of 71 patients in the Increlex program — it is not a theoretical risk.

United States (as of May 2026). IGF-1 LR3 is not FDA-approved for any human therapeutic indication. It has no approved drug application. It is sold as a research reagent (research chemical, not for human use) by suppliers operating in the gray-market peptide space. Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH. There is no FDA-approved adult or athletic indication for any IGF-1 product.

European Union (as of May 2026). Increlex (mecasermin) is authorized by the European Medicines Agency for the same pediatric severe primary IGFD indication. IGF-1 LR3 is not separately authorized.

WADA (as of May 2026). IGF-1 and its analogs — including IGF-1 LR3 — are listed under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are prohibited at all times, in and out of competition. Mongongu et al. (2020) published a validated detection assay specific to LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I in athlete samples.

Compounding pharmacies. Mecasermin is the compound a 503A or 503B compounding pharmacy can dispense — and only with a prescription and a clinical indication. IGF-1 LR3 specifically is not a compoundable product through standard pharmacy channels.

These four compounds all touch the GH/IGF-1 axis, but they act at different points and behave very differently. The table below organizes the practical differences.

Other compounds frequently discussed alongside IGF-1 LR3 sit either upstream (GH secretagogues), parallel (other tissue-repair peptides), or in the broader recomposition category. Each linked protocol page covers its own dosing, evidence, and safety profile.

IGF-1 LR3 directly relates to the IGF pathway rather than simply nudging GH pulses. Monitoring focuses on glucose handling, IGF-axis context, cardiovascular risk, and symptoms that may suggest excessive pathway activity.